Thanks for the thoughts. This is a really good topic for discussion.
So in terms of CAR-T / DART / TCR out there right now, I see Hutchinson (JUNO) has an AML MDS trial going on right now, NVS has some preclinical on CD123.
Juno looks like theyre using a TCR approach (i think). Novartis CAR-T. Macrogenics using the CD123 DART.
Is there any human data to see if these approaches will work in humans in the AML MDS indications? It's clear in the indications such as DLBCL, ALL, etc., CART, BITE approaches are doing something incredibly special. What would be the primary reasons one would expect similar results in AML MDS as seen in DLBCL ALL? Or, what would be the primary reasons you would NOT see similar results?
AML is a nasty disease and the indication is wide open right now for a massive groundbreaker (with the exception of what AGIO has done in those specific mutations). So, if MGNX DART could show what CAR-T has shown in other blood disorders, obviously could be huge for the stock.
thanks...
